Clinical Research Directory
Browse clinical research sites, groups, and studies.
Vitamin K2 Supplementation in Adult Episodic Migraine
Sponsor: Sola Aoun Bahous, M.D. Ph.D.
Summary
Migraine is a debilitating illness and a major cause of disability in the world. It is highly prevalent, especially among women. Vitamin supplementation is a potential therapeutic option for migraines that remains largely under-explored. Several studies have shown that people with migraine tend to have higher arterial stiffness than people without migraine. Vitamin K2 deficiency is an important mediator of arterial stiffness and calcification due to decreased carboxylation of matrix Gla protein (MGP). Supplementation reverses these changes and improves vascular health in patients with end stage renal disease according to previous studies. Therefore, vitamin K2 supplementation could serve a potential role in migraine patients. The purpose of the study is to test the effect of vitamin K2 on decreasing the frequency of migraine attacks and decreasing arterial stiffness. The population will be recruited from the neurology clinic at LAU Medical Center-Rizk Hospital and will constitute of adult patients. They will be randomized to receive either the supplement of vitamin K2 or a placebo for the duration of 6 months. Laboratory tests and arterial stiffness measurements will be done at the beginning, middle, and at the end of the study for comparison.
Official title: Efficacy of Vitamin K2 Supplementation in Adult Episodic Migraine
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
160
Start Date
2024-03-06
Completion Date
2026-12
Last Updated
2025-11-18
Healthy Volunteers
No
Interventions
Vitamin K2 or menaquinone-7
Vitamin K2 (MK7) 360 mcg/day orally once daily for 6 months
Placebo
Placebo pills will be administered orally once daily for 6 months
Locations (1)
Lebanese American University Medical Center - Rizk Hospital
Beirut, Beyrouth, Lebanon